Key Highlights

  • BioPharma Credit PLC USD (LSE:BPCP) offers a Dividend Yield of 7.10% from its US dollar share line.
  • The company targets a base dividend of 7 cents per share each year, paid in four quarterly instalments of 1.75 cents.
  • Special dividends from excess income lifted total payouts to 9.95 cents for 2025, 10.18 cents for 2024 and 10.21 cents for 2023.
  • Income comes from Debt secured on royalties and sales of approved life sciences products, giving contractual cash flows.

Business Model and Listing

BioPharma Credit PLC (LSE:BPCP) is the only listed specialist investor in life sciences debt on the London market and is a constituent of the FTSE 250. The company joined the London Stock Exchange on 27 March 2017 and lends to pharmaceutical and biotechnology businesses, with loans secured by royalties or cash flows from approved medical products.

The objective is straightforward: deliver long-term Shareholder returns predominantly through sustainable income distributions. The dollar-denominated share line trades with a dividend yield of 7.10%, and shareholders can elect to receive payments in sterling.

Dividend Policy: Base Plus Specials

The company pays and continues to target a base dividend of 7 cents per share per year, split into four quarterly payments of 1.75 cents. On top of that, the board typically adds special distributions from excess income, usually in the fourth quarter and sometimes also in the third quarter, when it judges this appropriate.

That structure explains the attractive headline record. Total dividends reached 10.21 cents for 2023, 10.18 cents for 2024 and 9.95 cents for 2025. In February 2026, the board declared a combined payment of 3.196 cents, comprising the 1.75 cent ordinary dividend and a special of 1.446 cents, which completed the 2025 distribution. After that payment, total dividends since the 2017 listing reached 76.88 cents per share.

Recent Distributions in 2026

The quarterly rhythm has continued without interruption through 2026. A 1.75 cent dividend for the first quarter was paid on 29 May 2026, and the second quarter instalment of 1.75 cents was paid on 31 July 2026. On 30 September 2026, the board declared the third quarter dividend, with an ex-dividend date of 8 October 2026 and a Record Date of 9 October 2026.

The share price has also firmed during the year. The shares traded at 92 cents in early February 2026, 93.60 cents in April, 95.40 cents in June and 98.40 cents at the close on 29 September 2026. The gradual rise has slightly compressed the yield but indicates improving market confidence in the Loan book.

Cash Flows and Payout Cover

Because the company must distribute nearly all its income to maintain Investment trust status, the payout is effectively governed by net interest income. The base dividend of 7 cents equals roughly 7% on a share price close to one dollar, and historical totals near 10 cents show that interest income has comfortably exceeded the base level in recent years.

The board designates dividends as interest distributions. This allows the company to reduce its corporation tax bill, while shareholders are treated for UK tax purposes as receiving interest. From a sustainability standpoint, this efficient structure supports cash available for distribution.

Dividend Growth Prospects

Dividend growth is not the main attraction. The base payment has remained at 7 cents for several years, and variation comes from specials. The trend in total payouts has eased slightly from 10.21 cents in 2023 to 9.95 cents in 2025, reflecting loan repayments, the timing of new deployments and Interest Rate movements on floating-rate assets.

Future specials will depend on the size of the portfolio, the level of prepayment fees and the interest rate backdrop. Lower US rates would reduce income on floating-rate loans, while new lending at attractive spreads could offset that pressure.

Risks Investors Should Weigh

The principal risk is credit performance. If a borrower's product underperforms or faces regulatory or Patent challenges, royalty-linked cash flows can weaken. Concentration is another factor, since the portfolio contains a limited number of large loans. Early repayments can also leave cash idle until it is redeployed, temporarily reducing income. For sterling-based investors, dollar exchange rates affect the value of each payment.

Is the Dividend Sustainable?

The base dividend at BioPharma Credit PLC (LSE:BPCP) looks well supported. The 7-cent target has been maintained through multiple interest rate cycles, and recent total payouts have run well above that level. The 7.10% yield is anchored by contractual, secured cash flows rather than discretionary earnings. Special dividends are less predictable and should be viewed as a Bonus rather than a promise. For income investors, the core quarterly payout appears durable, while the total annual return will continue to vary with portfolio activity.